Stocks and Investing
Stocks and Investing
Thu, December 21, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Graig Suvannavejh Maintained (AMLX) at Strong Buy with Decreased Target to $27 on, Dec 21st, 2023
Graig Suvannavejh of Mizuho, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy with Decreased Target from $46 to $27 on, Dec 21st, 2023.
Graig has made no other calls on AMLX in the last 4 months.
There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 0 agree with Graig's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Graig
- Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $36 on, Tuesday, December 12th, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $42 on, Friday, November 10th, 2023
- Chris Shibutani of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $40 on, Friday, November 10th, 2023
Contributing Sources